# EDGAR Filing Document

**Accession Number:** 0001954488
**File Stem:** 0001213900-26-002944
**Filing Date:** 2026-1
**Character Count:** 8330
**Document Hash:** 6794bff91af49a528dafbe6b407f5034
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-002944.hdr.sgml**: 20260109

**ACCESSION NUMBER**: 0001213900-26-002944

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20260109

**FILED AS OF DATE**: 20260109

**DATE AS OF CHANGE**: 20260109

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Jyong Biotech Ltd.
- **CENTRAL INDEX KEY:** 0001954488
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42701
- **FILM NUMBER:** 26523382

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 23F-3, NO.95, SEC. 1, XINTAI 5TH RD.
- **STREET 2:** XIZHI DIST.
- **CITY:** NEW TAIPEI CITY
- **PROVINCE COUNTRY:** F5
- **BUSINESS PHONE:** (8862) 27325205

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 23F-3, NO.95, SEC. 1, XINTAI 5TH RD.
- **STREET 2:** XIZHI DIST.
- **CITY:** NEW TAIPEI CITY
- **PROVINCE COUNTRY:** F5

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER<br> PURSUANT TO RULE 13a-16 OR 15d-16<br> UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of January 2026**

**Commission File Number: 001-42701**

**Jyong Biotech Ltd.**

**23F-3, No. 95, Section 1, Xintai 5<sup>th</sup> Road,<br> Xizhi District, New Taipei City,<br> Taiwan, 221** 

**(Address of principal executive office)**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

**Explanatory Note**

Jyong Biotech Ltd, a Cayman Islands exempted company (the "Company"), is hereby furnishing its unaudited interim balance sheet and unaudited interim statement of operations and comprehensive income (loss) for the six months ended June 30, 2025. The condensed consolidated financial statements furnished herein are unaudited and prepared by management of the Company. The financial statements are attached as Exhibit 99.1 to this report of foreign private issuer on Form 6-K.

**EXHIBIT INDEX**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | [Unaudited Interim Condensed Consolidated Balance Sheet as of June 30, 2025, and Unaudited Interim Condensed Consolidated statement of operations and comprehensive income (loss) for the Six months Ended June 30, 2025 and 2024.](ea027141801ex99-1_jyong.htm) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **Jyong Biotech Ltd.** | **Jyong Biotech Ltd.** |
| Date: January 9, 2026 | By: | /s/ Fu-Feng Kuo |
|  | Name: | Fu-Feng Kuo |
|  | Title: | Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1** 

**JYONG BIOTECH LIMITED**

**UNAUDITED INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS**<br> (in thousand US Dollars, except share and per share data)

---

| | | |
|:---|:---|:---|
|  | **As of**<br> **December 31,**<br> **2024** | **As of**<br> **June 30,**<br> **2025** |
|  | **Audited** | **Unaudited** |
| **ASSETS** | | |
| **Current Assets** | | |
| &nbsp;&nbsp;&nbsp;Cash | $**98** | $**132** |
| &nbsp;&nbsp;&nbsp;Restricted cash | **3** | **3** |
| &nbsp;&nbsp;&nbsp;Short-term investments | **-** | **16875** |
| &nbsp;&nbsp;&nbsp;Prepayments and other current assets | **105** | **153** |
| **Total current assets** | **206** | **17163** |
| &nbsp;&nbsp;&nbsp;Property and equipment, net | **3049** | **3358** |
| &nbsp;&nbsp;&nbsp;Operating right-of-use assets | **137** | **94** |
| &nbsp;&nbsp;&nbsp;Deferred offering costs | **934** | **-** |
| &nbsp;&nbsp;&nbsp;Restricted asset | **2034** | **2049** |
| &nbsp;&nbsp;&nbsp;Loan receivable from shareholder | **-** | **15000** |
| &nbsp;&nbsp;&nbsp;Other non-current assets | **6** | **7** |
| **Total non-current assets** | **6160** | **20508** |
| **TOTAL ASSETS** | $**6366** | $**37671** |
| **LIABILITIES AND SHAREHOLDERS' DEFICIT** |  |  |
| **Current liabilities** |  |  |
| &nbsp;&nbsp;&nbsp;Short-term bank loans | $**7225** | $**22436** |
| &nbsp;&nbsp;&nbsp;Notes and accounts payable | **3** | **3** |
| &nbsp;&nbsp;&nbsp;Accrued expenses | **1203** | **991** |
| &nbsp;&nbsp;&nbsp;Accrued expenses due to related parties | **147** | **219** |
| &nbsp;&nbsp;&nbsp;Current portion of long-term bank loans | **57** | **349** |
| &nbsp;&nbsp;&nbsp;Operating lease liabilities due to related parties-current | **159** | **131** |
| &nbsp;&nbsp;&nbsp;Other current liabilities | **3292** | **3366** |
| &nbsp;&nbsp;&nbsp;Other current liabilities due to related parties | **41** | **59** |
| **Total current liabilities** | **12127** | **27554** |
| &nbsp;&nbsp;&nbsp;Long-term loan from related parties | **5515** | **7195** |
| &nbsp;&nbsp;&nbsp;Long-term loan from third parties | **3131** | **3131** |
| &nbsp;&nbsp;&nbsp;Long-term bank loans, net of current portion | **2032** | **1945** |
| &nbsp;&nbsp;&nbsp;Operating lease liabilities due to related parties – non-current | **16** | **7** |
| &nbsp;&nbsp;&nbsp;Other non-current liabilities | **58** | **58** |
| &nbsp;&nbsp;&nbsp;Other non-current liabilities due to related parties | **628** | **628** |
| &nbsp;&nbsp;&nbsp;Guarantee liabilities | **19378** | **19625** |
| **Total non-current liabilities** | **30758** | **32589** |
| **TOTAL LIABILITIES** | **42885** | **60143** |
| **Commitments and contingencies** |  |  |
| **Shareholders' deficit** |  |  |
| &nbsp;&nbsp;&nbsp;Ordinary shares, $0.00001 par value; 5,000,000 thousand shares authorized; 73,361 thousand and 76,028 thousand shares issued and outstanding as of December 31, 2024 and June 30, 2025, respectively | **1** | **1** |
| &nbsp;&nbsp;&nbsp;Additional paid-in capital | **11805** | **28263** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Treasury shares, 1,794 thousand shares as of <br>December 31, 2024 and June 30, 2025 | **(16366)** | **(16366)** |
| &nbsp;&nbsp;&nbsp;Accumulated deficit | **(33080)** | **(34332)** |
| &nbsp;&nbsp;&nbsp;Accumulated other comprehensive income (loss) | **1121** | **(38)** |
| **Total shareholders' deficit** | **(36519)** | **(22472)** |
| **TOTAL LIABILITIES AND SHAREHOLDERS' DEFICIT** | $**6366** | $**37671** |

---

**JYONG BIOTECH LIMITED**

**UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)**

**(in thousand US Dollars, except share data in thousands and per share data)**

---

| | | |
|:---|:---|:---|
|  | **For the six months ended**<br> **June 30,** | **For the six months ended**<br> **June 30,** |
|  | **2024** | **2025** |
|  | **Unaudited** | **Unaudited** |
| **Operating expenses** |  |  |
| &nbsp;&nbsp;&nbsp;Research and development | $**(499)** | $**(367)** |
| &nbsp;&nbsp;&nbsp;Selling and marketing | **(21)** | **(20)** |
| &nbsp;&nbsp;&nbsp;General and administrative | **(431)** | **(429)** |
| **Total operating expenses** | **(951)** | **(816)** |
| **Loss from operations** | **(951)** | **(816)** |
| **Other incomes (expenses):** |  |  |
| &nbsp;&nbsp;&nbsp;Interest income | **6** | **24** |
| &nbsp;&nbsp;&nbsp;Interest expenses | **(448)** | **(417)** |
| &nbsp;&nbsp;&nbsp;Other gains (losses), net | **67** | **(43)** |
| **Total other expenses, net** | **(375)** | **(436)** |
| **Loss before income tax** | **(1326)** | **(1252)** |
| Income tax expense | **-** | **-** |
| **Net loss** | **(1326)** | **(1252)** |
| **Other comprehensive income (loss)** |  |  |
| &nbsp;&nbsp;&nbsp;Foreign currency translation adjustments, net of nil tax | **473** | **(1163)** |
| &nbsp;&nbsp;&nbsp;Unrealized gain on short term investments, net of nil tax | **-** | **4** |
| **Total other comprehensive income (loss)** | **473** | **(1159)** |
| **Total comprehensive loss** | $**(853)** | $**(2411)** |
| **Net loss per share:** |  |  |
| &nbsp;&nbsp;&nbsp;Basic and Diluted | $**(0.02)** | $**(0.02)** |
| **Weighted average shares outstanding (in thousands):** |  |  |
| &nbsp;&nbsp;&nbsp;Basic and Diluted | **71567** | **71758** |

---